Sofinnova Management VIII L.L.C. Continues to Hold Stake in Histogenics Corporation (NASDAQ:HSGX)

Sofinnova Management VIII L.L.C. held its position in Histogenics Corporation (NASDAQ:HSGX) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,077,040 shares of the biotechnology company’s stock at the end of the second quarter. Histogenics Corporation accounts for 2.1% of Sofinnova Management VIII L.L.C.’s holdings, making the stock its 9th largest position. Sofinnova Management VIII L.L.C. owned 9.37% of Histogenics Corporation worth $3,718,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Carl Domino Inc increased its position in Histogenics Corporation by 2.8% in the first quarter. Carl Domino Inc now owns 89,400 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,400 shares during the period. Renaissance Technologies LLC increased its position in Histogenics Corporation by 51.1% in the fourth quarter. Renaissance Technologies LLC now owns 99,000 shares of the biotechnology company’s stock worth $165,000 after buying an additional 33,500 shares during the period. Finally, Sabby Management LLC increased its position in Histogenics Corporation by 15.9% in the first quarter. Sabby Management LLC now owns 1,095,422 shares of the biotechnology company’s stock worth $1,895,000 after buying an additional 150,531 shares during the period. 50.09% of the stock is currently owned by institutional investors and hedge funds.

Histogenics Corporation (NASDAQ HSGX) traded up 2.63% during trading on Friday, reaching $1.84. 70,990 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $1.84 and a 200-day moving average price of $1.73. Histogenics Corporation has a 12 month low of $1.45 and a 12 month high of $4.47. The firm’s market cap is $40.79 million.

Histogenics Corporation (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.06. During the same quarter last year, the business earned ($0.61) EPS. On average, analysts forecast that Histogenics Corporation will post ($1.09) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by BNB Daily and is the property of of BNB Daily. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/14/sofinnova-management-viii-l-l-c-has-3718000-stake-in-histogenics-corporation-nasdaqhsgx-updated-updated-updated.html.

A number of equities analysts have recently weighed in on the stock. HC Wainwright set a $4.00 price target on shares of Histogenics Corporation and gave the stock a “buy” rating in a research note on Saturday, May 13th. Canaccord Genuity reaffirmed a “buy” rating and issued a $4.00 price target on shares of Histogenics Corporation in a research note on Friday. Zacks Investment Research downgraded shares of Histogenics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, ValuEngine raised shares of Histogenics Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $5.25.

Histogenics Corporation Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Institutional Ownership by Quarter for Histogenics Corporation (NASDAQ:HSGX)

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply